NeuroBo Pharmaceuticals Releases Corporate Presentation Update
NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July
Express News | Watching NeuroBo Pharmaceuticals; Zacks Small-Cap Research Gives Stock $22 Price Valuation
Express News | NeuroBo Pharmaceuticals Shares Are Trading Higher After the Company Announced the Dosing of the First Patient in the Multiple Ascending Dose Part 2 of Its Phase 1 Clinical Trial of DA-1726
Express News | NeuroBo Pharmaceuticals Inc: Planned Part 3 Interim Data Readout Expected Mid-2026 With Top-Line Data in Second Half of 2026
Express News | NeuroBo Pharmaceuticals: Top-Line Data Readout From Single Ascending Dose Part 1 Expected in Q3 2024 & From Multiple Ascending Dose Part 2 in Q1 2025
NeuroBo Pharmaceuticals Doses First Patient in MAD Part 2 of Phase 1 Trial for DA-1726 in Obesity Treatment; Top-Line Data for Part 1 Expected Q3 2024, Part 2 in Q1 2025; Planned Part 3 to Assess Weight Loss at 24 Weeks; $70M Financing to Fund Ongoing...
Express News | NeuroBo Pharmaceuticals Doses First Patient in the Mad Part 2 of Its Phase 1 Clinical Trial Evaluating Da-1726 for the Treatment of Obesity
NeuroBo Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
Continued Pre-Market Rally For NeuroBo Pharmaceuticals' (NRBO) Stock
NeuroBo Pharmaceuticals Raises $20 Million From Share Placement
Express News | NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced at-the-Market Under Nasdaq Rules
Express News | Dong-A ST (10%+) Buys 2.54M Shares of NeuroBo Pharmaceuticals at Avg Price of $3.13; Total Value Of $7,964,378.9
Express News | NeuroBo Pharmaceuticals: Warrants Expected to Provide Cash Runway to Complete Phase 1 Part 3 Clinical Trial
Express News | NeuroBo Pharmaceuticals Entered Into Definitive Agreement For Up To $70M Concurrent Private Placement And Registered Direct Offering Of 4,325,701 Shares At $3.93/Share
NeuroBo Pharmaceuticals Shares Rise on Positive Results for Weight-Loss Drug
Reported Earlier, NeuroBo's Novel Drug Shows Results for Weight Loss at ADA 2024
Express News | NeuroBo Pharmaceuticals - Da-1726 Also Exhibited Superior Glucose Lowering Compared to Survodutide
Express News | NeuroBo Pharmaceuticals' Da-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models
Goldman Sachs Raises Obesity Drug Market Estimate to $130B
No Data